ͼƬ dz̸ҩÎï´«ÊäϵͳÑо¿µÄ¼¸¸öÈȵã_»Æ½ð³ÇÓéÀÖ¨†±¸ÓÃÍøÖ·

»Æ½ð³ÇÓéÀÖ¨†±¸ÓÃÍøÖ·

µ±Ç°Î»ÖãºÖ÷Ò³ > ±ÏÒµÂÛÎÄ > ҽҩѧ > ҩѧ > >

dz̸ҩÎï´«ÊäϵͳÑо¿µÄ¼¸¸öÈȵã

À´Ô´::δ֪ | ×÷Õß:»Æ½ð³ÇÓéÀÖ¨†±¸ÓÃÍøÖ· | ±¾ÎÄÒÑÓ°Ïì ÈË

Õª¡¡Òª¡¡Í¨¹ý²éÔĽüÄê¹úÍâÎÄÏ×£¬Öصã½éÉÜÁËÒ©Îï´«Êäϵͳ½ÏеĽøÕ¹£¬ÓÐÂö³åʽ¸øÒ©ÏµÍ³£¬½á³¦¶¨Î»¸øÒ©ÏµÍ³¼°ÊÜÌåÐÍÓëÃâÒßÐͰÐÏòÖÆ¼ÁµÈÄÚÈÝ¡£

¡¡¡¡¹Ø¼ü´Ê£ºÒ©Îï´«Êäϵͳ¡¡Âö³åʽ¸øÒ©ÏµÍ³¡¡½á³¦¶¨Î»¸øÒ©ÏµÍ³¡¡ÊÜÌåÐÍÓëÃâÒßÐͰÐÏòÖÆ¼Á

¡¡¡¡Ò©Îï´«Êäϵͳ(Drug Delivery Systems,DDS)ϵָÈËÃÇÔÚ·ÀÖμ²²¡µÄ¹ý³ÌÖÐËù²ÉÓõĸ÷ÖÖÖÎÁÆÒ©ÎïµÄ²»Í¬¸øÒ©ÐÎʽ£¬ÔÚ60Äê´úÒÔǰµÄÒ©¼ÁѧÖгÆÎª¼ÁÐÍ¡£Èç×¢Éä¼Á¡¢Æ¬¼Á¡¢½ºÄÒ¼Á¡¢ÌùƬ¡¢ÆøÎí¼ÁµÈ¡£Ëæ×Å¿ÆÑ§µÄ½ø²½£¬¼ÁÐ͵ķ¢Õ¹ÒÑÔ¶Ô¶³¬Ô½ÆäÔ­ÓеÄÄÚº­£¬ÐèÒªÓÃÒ©Îï´«Êäϵͳ»ò¸øÒ©Æ÷(Device)ÕâÀàÊõÓï¼ÓÒÔ±íÊö£¬¼´Ô­ÓÉÒ©ÎïÓ븨ÁÏÖÆ³ÉµÄ¸÷ÖÖ¼ÁÐÍÒÑÂú×ã²»ÁËÁÙ´²ÖÎÁƵÄÐèÒª£¬ÓеĽ«Ò©ÎïÖÆ³ÉÊäעϵͳ¹©Óã¬ÓеÄÔò²ÉÓÃîѺϽðÖÆ³É¸øÒ©Æ÷Ö²ÈëÌåÄÚÓ¦Óã¬Ê¹ÁÙ´²ÓÃÒ©¸üÀíÏ뻯¡£Îª¿Ë·þÆÕÍ¨ÖÆ¼ÁµÄÓÐЧѪŨά³Öʱ¼ä¶ÌµÄȱÏÝ£¬³öÏÖÁ˳¤Ð§×¢Éä¼Á£¬¿Ú·þ³¤Ð§¸øÒ©ÏµÍ³»ò»º/¿ØÊÍÖÆ¼Á¡¢¾­Æ¤¸øÒ©ÏµÍ³µÈһϵÁÐеÄÖÆ¼Á¡£ÓÉÓÚ»º/¿ØÊÍÖÆ¼ÁµÄÌØµã£¬ËüµÄÊг¡Ç°¾°¿´ºÃ¡£»ºÊÍÖÆ¼Áͨ³£ÊÇÖ¸¿Ú·þ¸øÒ©ºóÄÜÔÚ»úÌåÄÚ»ºÂýÊÍ·ÅÒ©Îʹ´ïÓÐЧѪŨ£¬²¢ÄÜά³ÖÏ൱³¤Ê±¼äµÄÖÆ¼Á¡£¿ØÊÍÖÆ¼ÁϵָÊÍÒ©ËٶȽöÊܸøÒ©ÏµÍ³±¾ÉíµÄ¿ØÖÆ£¬¶ø²»ÊÜÍâ½çÌõ¼þ£¬ÈçpH¡¢Ã¸¡¢Àë×Ó¡¢Î¸³¦È䶯µÈÒòËØµÄÓ°Ïì£Û1£Ý£¬Êǰ´Éè¼ÆºÃµÄ³ÌÐò¿ØÖÆÊÍÒ©µÄÖÆ¼Á£¬ÈçÁã¼¶ÊÍÒ©µÄÉøÍ¸±Ã£¬Âö³åÊÍÒ©µÄ΢Í裬½á³¦¶¨Î»ÊÍÒ©µÄƬ¼Á»ò½ºÄÒÒÔ¼°×Ô¶¯µ÷½ÚÊÍÒ©µÄÒȵºËظøÒ©Æ÷µÈµÈ¡£ÒàÓÐЩÎÄÏ×¶Ô»ºÊÍ¡¢¿ØÊÍÖÆ¼Á²»¼ÓÑϸñÇø·Ö£¬Í³³ÆÎª»º/¿ØÊÍÖÆ¼Á¡£

¡¡¡¡¹úÍâÏÖÓйæ¸ñ²»Í¬µÄ»º/¿ØÊÍÖÆ¼ÁÉÌÆ·´ïÊý°ÙÖÖÒÔÉÏ£¬Æä¼ÁÐÍÒàÓÐÆ¬¼Á¡¢½ºÄÒ¡¢Ë¨¼Á¡¢ÉøÍ¸±Ã¡¢Í¸Æ¤ÌùƬ¡¢Ò©Ìõ¡¢Ö²Èë¼Á¡¢Õ³Ä¤Õ³¸½¼Á¼°×¢Éä¼ÁµÈ¶àÖÖÐÎʽ£¬ÆäÖÐÒÔ¿Ú·þ»º/¿ØÊÍÖÆ¼Á·¢Õ¹×î¿ì¡£»ºÊÍ΢Í轺ÄÒ¼ÁÓ뻺ÊÍÆ¬Ïà±È£¬¾ßÓа²È«ÏµÊý¸ßµÄÌØµã£¬Ò»¸ö½ºÄÒÊÇÓÉÉϰÙÁ£»ºÊÍ΢Íè×é³É£¬ÈôÓиö±ðСÍè½øÈë賦µÀºó·¢ÉúѸËÙ±À½âÊÍÒ©µÄÏÖÏ󣬯äÓ°ÏìÊÇ΢СµÄ£¬¶ø»ºÊÍÆ¬ÈôÓбÀÊÍÏÖÏó£¬ÒòÆäµ¥´Î¼ÁÁ¿±ÈÆÕÍ¨ÖÆ¼Á´ó£¬Æäºó¹ûÊDz»ÑÔ¶øÓ÷µÄÁË£»¶øÇÒ»ºÊÍ΢Í轺ÄÒ²»Ò×¶Ôθ¿ÕËÙÂÊÂýµÄ»¼Õß·¢Éúµþ¼ÓÊͷŵÄÏÖÏó£¬ÒÔ¼°²»Ò×ÊÜθҺpHÖµ±ä»¯µÄ¸öÌå²îÒìµÄÓ°Ïì¡£Òò´Ë£¬»ºÊÍ΢Í轺ÄұȻºÊÍÆ¬¸ü¾ßÓз¢Õ¹Ç°¾°¡£

¡¡¡¡ÎÒ¹úÔçÔÚ1977Äê°æµÄÖйúÒ©µä¾ÍÊÕÔØÁË·ÀÖÎѪÎü³æ²¡µÄûʳ×ÓËáÌàÄÆ»ºÊÍÆ¬£¬µ«ÔÚÕâ·½ÃæµÄÑо¿Ö±µ½80Äê´ú²Å±»¹ã·ºÖØÊÓ¡£1995ÄêÎÒ¹úÅú×¼µÄ»º/¿ØÊÍÖÆ¼Á¾ÍÓÐ7¸ö£¬Ö¬ÖÊÌ塢΢Çò¡¢ºÁ΢Á£µÈÑÇ΢Á£·ÖÉ¢¸øÒ©ÏµÍ³ÒÔ¼°½á³¦¶¨Î»¸øÒ©ÏµÍ³ÕâÀà¿Ú·þ°ÐÏò¸øÒ©ÖƼÁ¹úÄÚÑо¿Ò²ºÜ»îÔ¾(Ŀǰ֬ÖÊÌåÒÑÓÐÅú×¼Éú²úµÄÆ·ÖÖ)¡£½ñ¾ÍÒÔϼ¸¸ö²àÃæ½øÐиÅÊö¡£

1¡¡ÐÂÐÍ»º/¿ØÊÍÖÆ¼ÁÑо¿¸Å¿ö

1.1¡¡Î¸ÄÚÖÍÁôÐÍ¿ØÊ͸øÒ©ÏµÍ³£Û2£¬3£Ý¡¡¿É²ÎÔÄÓйØÎÄÏס£

1.2¡¡Âö³åʽ¸øÒ©ÏµÍ³¡¡¸ù¾Ýʱ³½Ò©ÀíѧÑо¿£¬Ò©ÎïµÄÖÎÁÆ×÷Óᢲ»Á¼·´Ó¦ºÍÌåÄÚ¹ý³Ì¾ùÓÐʱ¼ä½ÚÂÉ£¬ÕâÒѳÉΪÉè¼Æ¶¨Ê±ÊÍÒ©ÕâÀà¿ØÊÍÖÆ¼ÁµÄÖØÒªÒÀ¾Ý¡£ÊÍÒ©·½Ê½·ûºÏÈËÌåÖçÒ¹½ÚÂɱ仯µÄ¹æÂÉ£¬ÕâÊǽü´úÒ©¼ÁѧÑо¿µÄÒ»ÖÖÐÂÐÍÊÍҩģʽ¡£¹úÍâÓжà¼ÒÖÆÒ©ÆóÒµÕýÔÚÑо¿¿ª·¢ÕâÀàÂö³åʽ¸øÒ©ÏµÍ³£¬¹úÄÚÒàÒÑ¿ªÊ¼Ñо¿¡£

¡¡¡¡Âö³åÊÍҩϵͳ(pulsatile release system)¿Ú·þʱ½«ÒÔʱ¿ØµÄ·½Ê½ÔÚ賦µÀÄÚÌØ¶¨²¿Î»ÊÍ·ÅÒ©Îï¡£ÕâÀà¸øÒ©ÏµÍ³ÌØ±ðÊÊÓÃÓÚÒ¹¼ä»òÐѺóÂíÉÏÐèÒªÓÐÒ»¸öѪŨ·åÖµµÄ¼²²¡(ÈçʧÃß¡¢Ïø´­¡¢¹Ø½ÚÑס¢¾Ö²¿È±ÑªÐÔÐÄÔಡµÈ)£¬Ò²ÊÊÓÃÓÚÔÚ³¦µÀ½Ïϲ¿Î»´¦ÊÍÒ©ºÍÎüÊÕµÄÄÇЩ¼²²¡(Èç½á³¦°©¡¢À£ÑñÐԽ᳦Ñס¢¿Ú·þëÄÀàµÈ)¡£Ä¿Ç°¹úÍâͶÈëÕâÀàÑо¿µÄÖ÷ÒªÓÐÆ½´­Ò©¡¢ÐÄѪ¹ÜÒ©ºÍH2ÊÜÌå×è¶Ï¼Á¼°ÒȵºËصȡ£ÒýÈëעĿµÄÊÇALZA¹«Ë¾ºÍSearle¹«Ë¾¹²Í¬¿ª·¢µÄάÀ­ÅÁÃ×ÖçÒ¹½ÚÂÉÂö³åÊÍҩϵͳÉÌÆ·ÃûΪCalan- OROS¡£ÖÎÁÆÊµ¼ùÖ¤Ã÷£º¸ßѪѹ»¼Õß×î¼Ñ¸øÒ©Ê±¼äΪÇ峿3µã×óÓÒ£¬´Ëʱ»¼ÕßÌåÄÚ¶ù²è·Ó°·Ë®Æ½Ôö¸ß£¬ÐÄÔࡢѪ¹ÜÊÕËõ¼ÓÇ¿£¬Òò¶ø×î¿ÉÄܳöÎÊÌ⣬¸Ã¸øÒ©ÏµÍ³ÍíÉÏÁÙ˯ǰ·þÓ㬴ÎÈÕÇ峿¿ÉÊÍ·ÅÂö³å¼ÁÁ¿µÄÒ©Îʮ·Ö·ûºÏ¸Ã²¡½ÚÂɱ仯µÄÐèÒª£¬Ô¤¼Æ¸Ã¼ÁÐͺܿ켴¿ÉÉÏÊС£

1.2.1¡¡Âö³åÊÍҩƬ¡¡°´Ê±¿Ø±À½â»úÖÆ(time-controlled disintegration mechanism)Éè¼ÆµÄÒ»ÖÖ¸Éѹ°üÒÂÆ¬¿É´ïÂö³åÊÍҩ֮ĿµÄ¡£ÆäƬоÓÉÒ©ÎïÓë±À½â¼Á×é³É£¬ÆäÍâ¿ÇÊÇÓÉË®ÉøÍ¸ÐÔСµÄ¸´ºÏ²ÄÁÏ×é³É¡£µ÷½ÚÍâ¿Çºñ¶ÈÓëË®ÉøÍ¸ÐÔ¼´¿É¿ØÖÆÆäÂö³åÊÍҩʱ¼ä¡£ÀýÈ磺ÒÔÑÎËáÁòµª?NFDA1?ͪΪģÐÍÒ©Îï(ÔڽϿíµÄ賦µÀÄڿɱ»ÎüÊÕ)£¬Ñ¡ÓÃôȼ׻ùÏËÎ¬ËØ¸Æ(ECG-505)×÷±À½â¼Á£¬Ó²Ö¬ËáþΪÈ󻬼ÁÑ¹ÖÆ³ÉƬо¡£Íâ¿ÇÓÉÇ⻯±ÍÂéÓÍ(HCO)¡¢¾ÛÂÈÒÒÏ©(PVC)ºÍ¾ÛÒÒ¶þ´¼(PEG6000)»ìºÏ×é³É£¬²ÉÓÃ90¡«94¡æÈÛÈÚ·¨ÖÆÁ££¬È¡20Ä¿¿ÅÁ££¬ÒÔ¸Éѹ°üÒ·¨ÖÆÆ¬£¬µ÷½ÚPEGÓÃÁ¿¼°Íâ¿Çºñ¶È¼´¿É¿ØÖÆË®µÄÉøÍ¸ËÙÂÊ¡£ÕâÖÖϵͳµÄƽ¾ùʱÖÍΪ(7±1)h£¬´ËʱҩÎïÔÚ15 minÄÚÊÍ·ÅÍê±Ï¡£

1.2.2¡¡Âö³åÊÍҩ΢Íè£Û4£Ý¡¡Òà³ÆÊ±¿Ø±¬ÁÑϵͳ(time-controlled explosion system£¬TES)¡£ÕâÖÖÇòÐÎ΢ÍèµÄ½á¹¹¿É·Ö4²ã£¬´ÓÀïµ½Íâ·ÖÍèо¡¢Ò©Îï²ã¡¢ÅòÕͼÁ²ã¼°Ë®²»ÈÜÐÔ¾ÛºÏÎïÍâ²ãÒÂĤ£¬¼ûͼ1¡£µ±Ë®·Ýͨ¹ýÍâ²ãÒÂĤÏòϵͳÄÚÉøÍ¸£¬½Ó´¥ÅòÕͼÁ£¬Ò»µ©Ë®»¯ÅòÕͼÁµÄÅòÕÍÁ¦³¬¹ýÍâ²ãÒÂĤµÄ¿¹ÕÅÇ¿¶Èʱ£¬Ä¤¿ªÊ¼ÆÆÁÑ£¬´¥·¢Ò©ÎïÊÍ·Å¡£¿Éͨ¹ý¸Ä±äÍâ²ãÒÂĤµÄºñ¶ÈÀ´¿ØÖÆÊÍ·ÅÒ©ÎïµÄʱ¼ä¡£ÀýÈ磬ÍèоÓÃÌÇÍè(nonpareil)£¬ÆäÍâ²ãÒÀ´Î°üÉÏÒ©Îï²ã¡¢ÅòÕͲã(L-HPC)¼°Íâ²ãECĤ£¬µ±ÅòÕͲãºñ¶È(180 μm)¹Ì¶¨Ê±£¬ECĤ²ãµÄºñ¶È¿ÉÓ°ÏìÊÍÒ©µÄʱÖÍ(tL)£¬Èçθ¸´°²TES£¬ECĤºñΪ20 μmʱ£¬tLΪ1 h£»ECĤºñΪ25 μmʱ£¬tLΪ2 h£»ECĤºñΪ30 μmʱ£¬tLΪ3h¡£ÈôECĤ(25 μm)ºñ¹Ì¶¨£¬Ôòµ÷½ÚL-HPC²ãµÄºñ¶ÈÒà¿Éµ÷½ÚÊÍҩʱ¼ä£¬Èçtiap ride hydrochloride TES,ÔÚL-HPCΪ120 μmºñʱ£¬¾­Àú1hµÄʱÖͺóÊÍÒ©£¬µ«ÒÂĤ6hÒ²Î´ÆÆ£»ÈôL-HPCΪ180 μmʱ£¬2hºóÒÂĤ¿ªÊ¼ÆÆÁÑ£¬6hÄÚÈ«ÆÆ£¬Ò©ÎïÊÍ·Åͬ²½½øÐС£¡¡¡¡TES¿ÉÊÊÓÃÓÚ¸÷ÖÖÀí»¯ÐÔÖʲ»Í¬µÄÒ©Îï¡£ÕâÀà¸øÒ©ÏµÍ³¹úÄÚÒàÒÑ¿ªÊ¼Ñо¿¡£

1.3¡¡½á³¦¶¨Î»¸øÒ©ÏµÍ³£Û5¡«11£Ý¡¡½á³¦²¿Î»¼²²¡ÈçÀ£ÑñÐԽ᳦Ñס¢½á³¦°©µÈÒªÇóÄÜÔڽ᳦²¿Î»ÊÍÒ©£»´ËÍâ£¬Ëæ×ÅÉúÎ﹤³ÌµÄ·¢Õ¹£¬¶àëÄÀà¡¢µ°°×ÀàÒ©ÎïÔö¶à£¬ÕâÀàÒ©Îïͨ³£Òª×¢Éä¸øÒ©£¬ÒòËüÃÇÔÚ賦µÀÉ϶ÎÎȶ¨ÐÔ¼°ÎüÊÕÀûÓò¹Ê²»Ò˿ڷþ£¬¿ÉÊÇÔڽ᳦¶Î½µ½âµ°°×µÄøÀà½ÏÉÙ£¬ÍùÍùÎüÊÕÀûÓýϺã¬ÈôÄÜÖÆ³É½á³¦¶¨Î»¸øÒ©ÏµÍ³£¬Ôò¶àëÄÀà¡¢µ°°×ÀàÒ©Îï¿Ú·þ¸øÒ©¾ÍÓÐÏ£Íû£¬Òò¶ø¹úÄÚÍâ¾ùÖÂÁ¦ÓÚÑÐÖÆ¿ª·¢ÕâÀàÐÂÐ͸øÒ©ÏµÍ³¡£ÕâÀà¸øÒ©ÏµÍ³Í¨³£¿ÉÓÉÏÂÁм¸ÖÖ²ÄÁÏÖÆ³É¡£

1.3.1¡¡pHÃô¸ÐµÄ³¦ÈܲÄÁÏ¡¡²ÉÓÃË«²ãÒÂĤ¿ØÖÆÒ©ÎïÔڽ᳦²¿Î»ÊÍ·Å¡£È磺½«ÏûÑ×Í´(25%W/W)¡¢ÈéÌÇ(62%W/W)¡¢µí·Û(10%W /W)»ìÔÈ£¬ÒÔ10%(W/V)PVPË®ÈÜҺʪÈóÖÆÁ££¬55¡æ¸ÉÔÕûÁ£ºó¼Ó1%M.S£¬ÒÔΦ 4.5 mm°¼³åѹƬºó°üHPMC»ºÊÍÒ²ã(ÔöÖØ35.7%£¬Å䷽Ϊ£ºMethocel K15 5.0,PEG400 1.0,Talc 2.0,PVP 2.5£¬ÒÒ´¼84.0£¬Ë®5.5)£¬ÔÙ°ü³¦Ò²ã(ÔöÖØ5%£¬Å䷽Ϊ£º8%(W/V)Eudragitl,2%DEP)¡£ÕâÀà²ÄÁÏÒ×Êܳ¦µÀpHÖµ±ä»¯µÄÓ°Ïì¡£

1.3.2¡¡Ê±¿ØÐͲÄÁÏ¡¡Í¨³£Ê³ÎïÔÚθ¼°Ð¡³¦·Ö±ðÖÍÁôÔ¼3h×óÓÒ£¬ËùÒÔʳÎïÔËÐÐÖÁ½á³¦Ô¼Ðè5¡«7h¡£ÈôÄÜ¿ØÖÆÔÚ5¡«7hÊÍÒ©Õß¼´¿É´ï½á³¦¸øÒ©Ö®Ð§¡£Ç°Êöʱ¿ØÐÍÂö³åÊÍҩϵͳ¼´Êô´ËÀ࣬ÕâÀà¸øÒ©ÏµÍ³Òò¸÷ÈËθÅÅ¿ÕËÙÂʲ»Í¬£¬ËùÒÔ¸öÌå²îÒì½Ï´ó¡£

1.3.3¡¡Ã¸Ïû»¯ÐͲÄÁÏ¡¡ÀûÓý᳦²¿Î»ÌØÓеÄ΢ÉúÎïËù²úÉúµÄø£¬ÒÔ½µ½â¸ß·Ö×Ó²ÄÁ϶øÊÍÒ©£¬ÀýÈ磬żµª¾ÛºÏÎï¡¢¹û½ºµÈ¿É±»½á³¦ÖÐÌØÓеÄ΢ÉúÎïø½µ½â¶øÊÍÒ©¡£ÕâÀà²ÄÁϽ᳦¶¨Î»µÄרÊôÐÔ½ÏǰÁ½ÀàÇ¿¡£

1.3.4¡¡ÆäËû¡¡²ÉÓÃ¸ßÆµ½ºÄÒ£¬ÔÚ½º¿ÇÉÏ×°Ò»¸ö΢ÐÍÏßȦ£¬ÔÚ¸ßÆµ´Å³¡×÷ÓÃÏÂÏßȦ²úÉúµçÁ÷£¬Òý·¢½º¿ÇÆÆÁѶøÊÍÒ©¡£

1.4¡¡×Ô¶¯µ÷½Ú¸øÒ©ÏµÍ³£Û12£¬13£Ý¡¡¿É²ÎÔÄÓйØÎÄÏס£

2¡¡°ÐÏò¸øÒ©ÏµÍ³Ñо¿ÏÖ×´

¡¡¡¡ÔÚÁÙ´²ÖÎÁƼ²²¡µÄ¹ý³ÌÖÐÍùÍùÐèÒªÌá¸ßÒ©ÎïµÄ°ÐÏòÐÔ£¬ÒÔÆÚ×î´óÏ޶ȵØÔöǿҩÎïµÄÁÆÐ§£¬Í¬Ê±Ê¹Ò©ÎïµÄ²»Á¼·´Ó¦½µÖÁ×îµÍ£¬Òò´Ë°ÐÏò¸øÒ©ÏµÍ³(TDDS)ÒѳÉΪÏÖ´úÒ©¼ÁѧµÄÖØÒªÄÚÈÝ¡£Í¨³£¿É½«¿ØÊÍÖÆ¼Á·Ö³ÉÁ½´óÀࣺһÀàרÃÅÑо¿ÈçºÎ¿ØÖÆÖƼÁÖÐÒ©ÎïÊͷŵÄËÙ¶È£¬¼´Áã¼¶¡¢Ò»¼¶»¹ÊÇÂö³åʽÊÍÒ©£¬ÒÖ»ò×Ôµ÷ʽÊÍÒ©µÈµÈ(ÒÑÔÚǰÊöÄÚÈÝÖÐÌÖÂÛ)£»ÁíÒ»ÀàרÃÅÑо¿ÈçºÎ¿ØÖÆÖƼÁÖÐÒ©ÎïÊͷŵÄÈ¥Ïò£¬ÕâÊÇÒ»ÀàÒªÇó¸ü¸ß¡¢ÄѶȸü´óµÄÐÂÖÆ¼Á£¬Òò¶ø½«Æä¹éÊôÓÚ°ÐÏòÖÆ¼Á½øÐе¥ÁÐÌÖÂÛ¡£

2.1¡¡°ÐÏò¸øÒ©ÖƼÁµÄ·ÖÀà

2.1.1¡¡°´¸øÒ©Í¾¾¶·Ö¡¡È«Éí×÷ÓðÐÏò¸øÒ©ÖƼÁ£¬¼´Í¨¹ý¿Ú·þ»ò×¢ÉäµÈ·½Ê½¸øÒ©ºó£¬ÄÜʹҩÎïµ¼ÏòËùÐè·¢»Ó×÷ÓõIJ¿Î»£»·ÇÈ«Éí×÷ÓõİÐÏò¸øÒ©ÖƼÁ£¬¼´¾Ö²¿ÓÃÒ©ºó£¬Ò©Îï¾ÍÔڸò¿Î»·¢»ÓÖÎÁÆ×÷Óá£

2.1.2¡¡°´×÷Ó÷½Ê½·Ö¡¡Ö÷¶¯°ÐÏò(active targeting)¸øÒ©ÖƼÁ¾ßÓÐʶ±ð°Ð×éÖ¯»ò°Ðϸ°ûµÄ´ó·Ö×Ó£¬ÒÔÆäÎªÔØÌåµÄÄÜÁ¦£»±»¶¯°ÐÏò(passive targeting)¸øÒ©ÖƼÁ£¬ÏñÖ¬ÖÊÌ塢΢Çò¡¢ºÁ΢Á£¡¢Èé¼Á»ò¸´ÈéµÈ΢Á£ÔØÌåÖÆ¼Á£¬¶Ô°Ðϸ°û²¢ÎÞʶ±ðÄÜÁ¦£¬µ«¿É¾­ÑªÑ­»·µ½´ïËüÃDz»ÄÜͨ¹ýµÄëϸѪ¹Ü´²£¬²¢Ôڸò¿Î»ÊÍÒ©¡£

2.1.3¡¡°´Ò©Îï×÷ÓÃˮƽ·Ö¡¡Ò»¼¶°ÐÏò£¬Èç΢Á£ÔØÌåÖÆ¼ÁÖ»Äܽ«Ò©ÎïÊäËÍÖÁÌØ¶¨µÄÆ÷¹Ù£»¶þ¼¶°ÐÏò£¬ÏµÖ¸Äܽ«Ò©ÎïÊäËÍÖÁijÆ÷¹ÙµÄÌØ¶¨²¿Î»£»Èý¼¶°ÐÏò£¬ÏµÖ¸Äܽ«Ò©ÎïÊäËÍÖÁÌØ¶¨²¿Î»µÄ²¡±äϸ°ûÄÚ¡£ÈçÈôÄܽ«Ò©ÎïÖÆ³ÉÈý¼¶°ÐÏòÖÆ¼Á£¬Ôò¿ÉʹҩÎïÔÚϸ°ûˮƽÉÏ·¢»Ó×÷Óã¬Ò©Îï¿ÉרÃŹ¥»÷²¡±äϸ°û£¬¶ÔÕý³£Ï¸°ûûÓлò¼¸ºõûÓв»Á¼µÄÓ°Ï죬¿ÉʹҩÎïµÄÁÆÐ§´ïµ½×îÀíÏëµÄ³Ì¶È¡£

2.1.4¡¡°´ÎïÀíÐÎ̬·Ö¡¡Ë®²»ÈÜÐÔÖÆ¼ÁÖ¸Ö¬ÖÊÌ塢΢Çò¡¢ºÁ΢Á£¡¢Èé¼Á»ò¸´ÈéµÈË®²»ÈÜÐÔ΢Á£ÔØÌåÖÆ¼Á£»ÁíÒ»ÀàÊÇË®ÈÜÐÔµÄÌØÒì»ò·ÇÌØÒìÐÔ´ó·Ö×ÓÔØÌåÖÆ¼Á£¬°üÀ¨ºÏ³É´ó·Ö×ÓÓëÌìÈ»µÄÉúÎï´ó·Ö×Ó(Èç¾Û¶àÌÇ¡¢¿¹Ìå¡¢ºËÌÇ¡¢ºËËáµÈ)ÔØÌåÖÆ¼Á£¬Ò©ÎïµÄ°ÐÏòÖ÷Ҫƾ½èÔØÌåϵͳÀ´ÊµÏÖ£¬¹ÊÓֿɳÆÎªÒ©ÎïÔØÌåϵͳ (drug-carrier systems)¡£

ÎÄÏ××ÊÁϾ­³£²ÉÓÃÖ÷¶¯°ÐÏòÓë±»¶¯°ÐÏò¸øÒ©ÖƼÁµÄ·ÖÀà·¨¡£

¡¡¡¡ÔÚÒÔÍùÑо¿ÖУ¬±»¶¯°ÐÏò¸øÒ©Ñо¿½Ï¶à£¬ÈçÖ¬ÖÊÌåµÈ΢Á£ÔØÌåÖÆ¼Á£¬½øÈë»úÌåºó£¬¿É°´ÆäÁ£¾¶´óС·Ö²¼ÓÚ²»Í¬µÄÔàÆ÷£º¾²Âö×¢Éä7¡«12 μmµÄ΢Á££¬¿É±»·Î²¿»úеÐÔ½ØÂ˶øÉãÈ¡£»¶¯Âö×¢Éä´óÓÚ12 μmµÄ΢Á££¬¿É×èÖÍÓÚëϸѪ¹Ü´²¶øµ½´ï¸Î¡¢ÉöºÉÁöÆ÷¹ÙÖУ»¾²Âö¡¢¶¯Âö»ò¸¹Ç»×¢Éä0.1¡«0.2 μmµÄ΢Á££¬ºÜ¿ì±»Íø×´ÄÚÆ¤ÏµÍ³(RES)µÄ¾ÞÊÉϸ°ûÍÌÊÉ×îÖÕµ½´ï¸ÎÔà¿Ý·ñÊÏϸ°ûµÄÈÜøÌåÖС£

2.2¡¡°ÐÏò¸øÒ©ÏµÍ³·¢Õ¹Ç÷ÊÆ¡¡Îª½øÒ»²½Ìá¸ßÒ©ÎïµÄ°ÐÏòÐÔ£Û14£¬15£Ý£¬¿ÆÑ§¼ÒÃÇÓÖ½«ÄÜʶ±ð°Ðϸ°ûµÄ´ó·Ö×ÓÁ¬½ÓÓÚÒ©ÎïÔØÌåµÄ±íÃæ(»òÓëÒ©Îï·Ö×ÓÖ±½ÓÏàÁª)£¬È磺½«µ¥¿Ë¡¿¹ÌåÁ¬½ÓÓÚº¬Ò©Ö¬ÖÊÌå(»òºÁ΢Á£)µÄ±íÃæ£¬¿ÉÌá¸ßÒ©Îï¶ÔÖ×Áöϸ°ûµÄ°ÐÏòÐÔ£¬µ«ÒòʵÌåÁöÄÚѪ¹©²î£¬ËüÏòÁöÌåÄÚ²¿°ÐÏòµÄЧ¹ûÒà²î£»½ø¶øÑÐÖÆÈËÊóǶºÏ¿¹Ö×Áöϸ°ûºËµ¥¿Ë¡¿¹Ìå(chTNT)Ö¬ÖÊÌ壬ʹÆä°ÐÏòʵÌåÁöÄÚµÄЧ¹û±Èµ¥¿¹Ö¬ÖÊÌå´óΪÌá¸ß£¬ÕâÖÖÃâÒßÐÍÖ¬ÖÊÌå×÷ΪҩÎï´«ÊäϵͳµÄÑо¿±¨µÀËäΪÊý²»¶à£¬µ«Ä¿Ç°ÒÑÊܹúÄÚÍâѧÕߵįձ鹨ע¡£

¡¡¡¡Ñо¿±íÃ÷¶àÊýÖ×Áöϸ°û±íÃæÉϵÄÒ¶ËáÊÜÌ壬ÔÚÊýÁ¿ºÍ»îÐÔÉϾù±ÈÕý³£Ï¸°û´óµÃ¶à£¬Òò¶ø¿ÉÖÆ±¸Ò¶ËáÖ¬ÖÊÌ壬ËüÒÔÒ¶ËáÊÜÌåΪ½éµ¼£¬Ìá¸ßÁËÖ¬ÖÊÌå¶ÔÖ×Áöϸ°ûµÄ°ÐÏòÐÔ¡£

¡¡¡¡Ò¶ËáÖ¬ÖÊÌåÒ×µ¼Ïò“½¡¿µ”Ö×Áöϸ°ûĤ£¬¹ÊΪ·ÇÍíÆÚÖ×ÁöÖÎÁÆÒ©ÎïµÄÓÅÁ¼´«Êäϵͳ£»chTNT-Ö¬ÖÊÌåÒ×´©Í¸“²»½¡¿µ”Ö×Áöϸ°ûĤ¶ø°ÐÏòϸ°ûºË£¬¹ÊΪÍíÆÚÖ×ÁöÖÎÁÆÒ©ÎïµÄÓÅÁ¼´«Êäϵͳ£¬ÕâÑùÁ½ÖÖ²»Í¬µÄ°ÐÏòÖ¬ÖÊÌå¿ÉÓÃÓÚÖÎÁƲ»Í¬Éú³¤ÆÚµÄ¹ãÆ×Ö×Áö¡£

¡¡¡¡1966ÄêMorellµÈ·¢ÏÖ²¸È鶯ÎïµÄ¸ÎʵÖÊϸ°ûĤ±íÃæ´æÔÚÈ¥ÍÙÒºËáÌǵ°°×ÊÜÌå(Asialoglycoprotein receptor,ASGPr)£¬¸ÃÊÜÌåÄÜרһÐÔµØÊ¶±ðÒÔ°ëÈéÌÇΪ¶Ë»ùµÄÌǵ°°×£¬Òò¶øÒÔÕâÑùµÄÌǵ°°×ÎªÔØÌ壬¿É½«Ò©Îïµ¼Ïò¸ÎʵÖÊϸ°û(¸Î·ÇʵÖÊϸ°û(¿Ý·ñÊÏϸ°ûºÍÄÚÆ¤Ï¸°û)µÄ±íÃæÓиʶÌÇÊÜÌå)£¬²¢Ö÷¶¯Ïò¸Îϸ°ûµÄÈÜøÌåתÔË£¬¶øÊÜÌå±¾ÉíÓÖÄÜÖØÐ»ص½Ï¸°ûĤ¡£

¡¡¡¡Ä¿Ç°¹úÄÚÍâ¶ÔÊÜÌåÐÍÓëÃâÒßÐͰÐÏòÖÆ¼ÁÑо¿±¨µÀ½Ï¶à£¬Í¨¹ýÕâÁ½Öֽ鵼·½Ê½ÒÔÌá¸ßÒ©ÎïµÄ°ÐÏòÐÔ£¬Ê¹Ò©Ð§·¢»ÓµÃ×îºÃ£¬²»Á¼·´Ó¦½µÖÁ×îС¡£

¡¡¡¡»¹¿É½«Ò©ÎïÖÆ³É´ÅÐÔÖÆ¼Á£¬ÒÔÌá¸ßÒ©ÎïµÄ°ÐÏòÐÔ£¬È纬³¬Î¢´ÅÁ£µÄÑÎËá°¢Ã¹ËØµ°°×΢Çò£¬¶¯Âö×¢Éäºó£¬ÔÚ°ÐÇøÌåÍâ´Å³¡µÄÒýµ¼Ï£¬Æä°ÐÇøÒ©ÎïŨ¶È±È¾²Âö×¢Éäͬ¼ÁÁ¿µÄÓÎÀë°¢Ã¹ËØ¸ß³ö100±¶¡£ÁÙ´²ÊÔÑé±íÃ÷£¬´ÅÐÔÖÆ¼ÁÖеĴÅÐÔ³¬Î¢Á£×Ó¿ÉÒÔ¶¨ÆÚ°²È«µØ±»ÅųöÌåÍâ¡£µ«ÉдæÔڴų¡µÄÇ¿¶È¡¢ÌݶÈÓ듾۽¹”ÎÊÌ⣬´Å³¡ÊÇ·ñ»á¸Ä±äºìϸ°ûµÄ»úÄܺ͸ıäѪÁ÷µÄ·½Ê½µÈÎÊÌ⣬¾ùÓдý½øÒ»²½Ñо¿¡£

¡¡¡¡µÍÃܶÈÖ¬µ°°×(LDL)£Û16£ÝÊÇ´æÔÚÓÚ²¸È鶯ÎïѪ½¬ÖеÄÖ¬µ°°×¡£ÈËѪ½¬ÖÐLDL¿ÉЯ´øÑª½¬µ¨¹Ì´¼×ÜÁ¿µÄ2/3£¬ÊÇϸ°ûÍâÔ´ÐÔµ¨¹Ì´¼µÄÖ÷ÒªÀ´Ô´¡£LDLÌåÄÚ´úлÖ÷Òª¾­ÓÉϸ°ûĤ±íÃæµÄÌØÒìÐÔLDLÊÜÌåʶ±ð£¬´Ó¶ø½øÈëϸ°ûÄÚ±»ÀûÓã¬ÔÚϸ°ûÄÚµÄÄÚÔ´ÐÔµ¨¹Ì´¼²»ÄÜÂú×ãÐèҪʱ£¬Í¨¹ýµ÷½Úϸ°ûĤÉÏLDLÊÜÌåµÄÊýÄ¿ºÍ»îÐÔ£¬ÒÔÔö¼Ó¶ÔLDLµÄÎüÊÕ¶øÔö¼Ó¶ÔÍâÔ´ÐÔµ¨¹Ì´¼µÄÀûÓá£LDLÖ÷Òª¾­¸ÎÄÚÌØ¶¨µÄLDLÊÜÌåÇå³ý¡£°©Ï¸°û³£¾ßÓÐÄÚÔ´ÐÔµ¨¹Ì´¼ºÏ³ÉÕϰ­£¬ÇÒÓÉÓÚÆä´óÁ¿ÔöÖ³¸´ÖÆ£¬Ï¸°ûĤ¶Ôµ¨¹Ì´¼µÄ´óÁ¿ÐèÇó£¬Ï¸°û±íÃæLDLÊÜÌåµÄ»îÐÔ¼°ÊýÁ¿ÔÚijЩ°©Ï¸°ûÖи߳öÕý³£Ï¸°û20±¶ÒÔÉÏ£¬Òò´Ë£¬²ÉÓÃLDLºÉÔØ¿¹°©Ò©Î¿É´ó´óÌá¸ß¶ÔijЩ°©Ï¸°ûµÄ°ÐÏòÐÔ¡£LDLÊÇÄÚÔ´ÐÔÖ¬µ°°×£¬½«Ëü×÷ΪҩÎïÔØÌ壬¼´¿É±ÜÃâÖ¬ÖÊÌå¡¢µ¥¿Ë¡¿¹ÌåµÈÔÚÌåÑ­»·Öб»Íø×´ÄÚÆ¤ÏµÍ³Ñ¸ËÙÇå³ýµÄÎÊÌ⣬ÓÖ¿ÉÃÖ²¹Ò»°ãÔØÌå´æÔڵİÐÏòÐÔ²îµÄ²»×㣬Õâ¶Ô½â¾öµ±Ç°¿¹°©Ò©ÎﻯÁÆÖдæÔڵİÐÏòÐԲ²»Á¼·´Ó¦´óµÄÎÊÌâ¾ßÓÐÖØÒªÒâÒå¡£

¡¡¡¡ÔÚϸСµÄÒ©ÎïÔØÌå΢Á£½øÈëÌåÑ­»·Ê±Ò×±»RESµÄ¾ÞÊÉϸ°ûÍÌÊÉ£¬´Ó¶øÓ°ÏìÒ©Îïµ½´ïËùÐèÖÎÁƵİÐÇø£¬¹Ê´Ë£¬»Ø±ÜRESµÄÍÌÊÉ×÷ÓÃÒѳÉΪҩÎïÔØÌå°ÐÏòÐÔµÄÖØµã¿ÎÌâÖ®Ò»£Û17£¬18£Ý¡£Èô½«¿Õ°×ÔØÌåÏÈÓÃRES±¥ºÍ£¬È»ºóÔÙ¸øº¬Ò©ÔØÌ壬¼´¿ÉÖ±´ï°ÐÇø£¬µ«´Ë¾Ù»áʹ»úÌåÃâÒß¹¦ÄÜÊÜË𣬲¢°é·¢ÆäËû¼²²¡£¬¹Ê´Ë·¨²»¿ÉÈ¡£»ÈôÒÔ»úÌåÄÚÔ´ÐÔÎïÖÊÈçLDLÎªÔØÌ壬Ôò¿É»Ø±ÜRESµÄÍÌÊÉ¡£½üÄêÀ´Ñо¿½Ï¶àµÄÊǻرÜRESµÄÃâÒßÖ¬ÖÊÌå(RES-avoiding immunoliposomes)£¬¼´ÔÚº¬Ò©Ö¬ÖÊÌåµÄ±íÃæ¼ÈÓÐIgGÃâÒß¿¹Ì壬ÓÖ¹üÒÔPEG£¬¼ûͼ2¡£ÕâÑù¼È»Ø±ÜÁ˾ÞÊÉϸ°ûµÄÍÌÊÉ£¬Óֿɽ«Ò©Îïµ¼Ïò°Ðϸ°û¡£PEG¿É»Ø±ÜRESÍÌÊɵĻúÖÆËäδÍêÈ«¸ãÇ壬µ«ÕâÓëPEG·Ö×Ӿ߶ÀÌØ½á¹¹Óйأ¬¼´ÓëÆäÇ¿Ç×Ë®ÐÔºÍÓÐÒ»¶¨µÄ÷·¸ï¡¡ÈÐÐÔÓйأ¬ÍƲâPGE¾ßÓÐÄ£·Â°×ϸ°û¡¢ºìϸ°û±íÃæ´æÔڵĶàÌÇ»ùÒòµÄ¹¦ÄÜ¡£ÓÖÈç»Ø±ÜRESµÄ·ÇÀë×Ó±íÃæ»îÐÔ¼ÁÄÒÅÝ(nonionic surfactant vesicles,NsVs¼´Niosomes)£¬ÓÉPEG2000-µ¨¹Ì´¼ÑÜÉúÎï(PEG-ch)ÖÆ³ÉµÄ³¤Ñ­»·°¢Ã¹ËØ·ÇÀë×Ó±íÃæ»îÐÔ¼ÁÄÒÅÝ(long circulation adriamycin NsVs,L-ADM-NsVs)£¬Æä±íÃæÉϵÄPEG²ãÔöÇ¿Á˸ÃÄÒÅݵÄÇ×Ë®ÐÔ£¬´Ó¶ø¼õÉÙRESµÄÍÌÊÉ£¬ÑÓ³¤ÑªÖÐÑ­»·Ê±¼ä£¬Ìá¸ß°ÐÏòÐÔºÍÒÖÁö»îÐÔ¡£

²Î¿¼ÎÄÏ×

¡¡1¡¡Ansel HC,Popovich NG,Allen LV.Pharmaceutical dosage forms and drug delivery systems.Williams & Wilkins Baltimore.6th ed.New York:Marcel Dekker Inc,1995.218¡«220

¡¡2¡¡Deshpande AA,Shah NH,Rhodes CT,et al.Development of a novel controlled-release system for gastric retention.Pharm Res,1997,14(6)¡Ã815

¡¡3¡¡Shalaby WSW,Blevins WE,Park K.In vitro and in vivo studies of enzyme-digesbible hydrogels for oral drug delivery.J Controlled Release,1992,19(1¡«3)¡Ã131

¡¡4¡¡Ueda S,Yamagulchi H,Kotani M,et al.Development of a novel drug release system,time-controlled explosion system(TES)¢ò.Chem Pharm Bull,1994,42(4)¡Ã246

¡¡5¡¡Bieck PR.Colonic drug absorption and metabolism.New York:Marcel Dekker Inc,1993.169¡«172

¡¡6¡¡Gazzanig A,Sangalli ME,Giordano F.Oral chronotopic drug delivery systems:achievement of time and/or sit specifity.Eur J Pharm Biopharm,1994,40(4)¡Ã246

¡¡7¡¡Rubinstein A,Radai R,Ezra M,et al.In vitro evaluation of calcium pectinate:a potential colon-specific drug delivery carrier.Pharm Res,1993,10(2)¡Ã258

¡¡8¡¡Ashford M,Fell J,Attwood D,et al.Studies on pectin formulations for colonic drug delivery.J Controlled Release,1994,30(3)¡Ã225

¡¡9¡¡Leopold CS,Friend DR.A dexamethasone-poly (L-aspartic acid) conjugate as potential prodrug for colon-specific drug delivery.Eur J Pharm Biopharm,1996,42(Suppl 1)¡ÃS485

10¡¡Bieck PR.Colonic drug absorption and metabolism.New York:Marcel Dekker Inc,1993.145¡«148

11¡¡Sako K,Nakashima H,Sawada T,et al.Relationship between gelation rate of controlled-release acetaminophen tablets containing ployethylene oxide and colonic drug release in dogs.Pharm Res,1996,13(4)¡Ã549

12¡¡Anderson JM,Kim SW,Kope¨¯ch J,et al.Advances in drug delivery systems 5.London£¬New York,Tokyo:Elsevier Amsterdam,1992.145¡«159

13¡¡Kitano S,Koyamay ,Kataoka K,et al.A novel drug delivery system utilizing a glucose responsive polymer complex between poly(vinyl alcohol)and poly(N-vinl-2-pyrrolidone)with a phenylboronic acid moiety.J Controlled Release,1992,19(1¡«3)¡Ã161

14¡¡Gottschalk S,Cristiano RJ,Smith LC,et al.Folate receptor mediated DNA delivery into tumor cells:potosomal disruption results in enhanced gene expression.Gene Ther,1994,1(1)¡Ã185

15¡¡Rojansakuly.Antisense oligonucleotide therapeutics:drug delivery and targeting.Adv Drug Delivery Rev,1996,18(2)¡Ã115

16¡¡Bijsterbosch MK,Berkel TJCV.Native and modified lipoproteins as drug delivery systems.Adv Drug Delivery Rev,1990,5(3)¡Ã231

17¡¡Herron JN,Gentry CA,Davies SS,et al.Antibodies as targeting moiesties:affinity measurements conjugation chemistry and applications in immanoliposomes.J Controlled Release,1994,28(1¡«3)¡Ã155

18¡¡Kuke I,Hayashi T,Tabata Y,et al.Synthesis of poly (ethylene glycol)derivatives with different branchings and their use for protein modification.J Controlled Release,1994,30(1)¡Ã27


»Æ½ð³ÇÓéÀÖ¨†±¸ÓÃÍøÖ·

ÈȰñÔĶÁTOP

±¾ÖÜTOP10

2050ÀýӲĤÍâ×èÖÍÒ©ÎïÀ©É¢ÔÙÈÏʶ

2050ÀýӲĤÍâ×èÖÍÒ©ÎïÀ©É¢ÔÙÈÏʶ

£ÛÕªÒª£Ý Ä¿µÄ ̽ÌÖӲĤÍâ×èÖͳõÁ¿ÔÚ²»Í¬´©´ÌµãµÄÀ©É¢Çé¿ö¡£×ÊÁÏÓë·½·¨ 2050ÀýӲĤÍâ×èÖͲ¡Àý£¬Ïêϸ¼Ç¼...